- Invisicare Patents Continue to be Granted Globally
LAS VEGAS, June 3 /CNW/ -- Skinvisible, Inc. (OTC Bulletin Board: SKVI)
(Website: http://www.skinvisible.com), the developers of Invisicare, a polymer
delivery system that enhances topically applied products, has been granted a
comprehensive patent in Australia. The Invisicare patent provides protection
in the areas of "Topical Composition, Topical Composition Precursor, and
Methods for Manufacturing and Using".
This patent will assist Skinvisible's sales efforts in Australia by
protecting its Invisicare technology and formulated products. Invisicare has a
unique ability to hold active ingredients on the skin for extended periods of
time while resisting wash-off, rub-off and perspiration. This benefit leads
to additional unique enhancements to topical dermatology products.
Additionally, Invisicare provides product life-cycle management by allowing
for new patent protection for products coming off patent and providing
improved claims to formulations of cosmetics, over-the-counter and
prescription skincare products.
"The demand for our Invisicare technology and out products is
international. A key component of our business strategy is to provide
patentable products to our clients," said Mr. Terry Howlett, President and CEO
of Skinvisible. "Having our Invisicare patent approved in Australia is one
more degree of protection that we can provide to our international licensees.
We continue to submit for patent protection worldwide for all products
formulated with Invisicare."
Australia has followed India as the second international patent approved
for Skinvisible. With numerous patents pending both for its technology and
formulated products, Skinvisible continues to remain focused on securing
licensees for its products internationally.
Skinvisible has patented its technology and trademarked its polymer
delivery system Invisicare(R). Invisicare is a combination of hydrophilic and
hydrophobic polymers that hold active ingredients on the skin for extended
periods of time. They are non-occlusive and allow normal skin respiration and
perspiration while moisturizing and protecting against exposure from a wide
variety of environmental irritants. See: http://www.invisicare.com
About Skinvisible Pharmaceuticals, Inc.
Skinvisible Pharmaceuticals is a research-and-development company whose
primary business objective is to license its proprietary formulations with
Invisicare(R) to pharmaceutical and cosmeceutical companies as well as
assisting companies in revitalizing or enhancing their existing skin care
products. Skinvisible receives a combination of research and development fees,
upfront license fees, and ongoing royalties for the life of the Invisicare
patent. See: http://www.skinvisible.com
This press release contains 'forward looking' statements within the
meaning of Section 21A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, and are subject to the
safe harbors created thereby. Such statements involve certain risks and
uncertainties associated with an emerging company. Actual results could differ
materially from those projected in the forward looking statements as a result
of risk factors discussed in Skinvisible, Inc. reports on file with the U.S.
Securities and Exchange Commission (including, but not limited to, a report on
Form 10Q for the quarter ending June 30, 2007).
Terry Howlett, President/CEO
Skinvisible Pharmaceuticals, Inc.
For further information:
For further information: Terry Howlett, President-CEO of Skinvisible
Pharmaceuticals, Inc., +1-702-433-7154, firstname.lastname@example.org Web Site: